0I3Q.LSE Corcept Therapeutics Incorporated

Healthcare Biotechnology London Exchange
- USD
Market cap
-
P/E
87.5x
P/B
-
ROE
3.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 0I3Q.LSE undervalued?

Graham number

The Graham number of Corcept Therapeutics Incorporated cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Corcept Therapeutics Incorporated fundamental analysis

No fundamental analysis for Corcept Therapeutics Incorporated yet.

Corcept Therapeutics Incorporated stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not ca…

Full company profile